| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 2037.1 | 1879.6 | 1679.3 |
| Other income | 20.5 | 19.8 | 17.5 |
| Total income | 2057.7 | 1899.4 | 1696.8 |
| Profit before exceptional items & tax | 70.1 | 41.9 | 68.9 |
| Profit before tax | 70.1 | 41.9 | 68.9 |
| Net profit | 56.1 | 33.2 | 55.5 |
| Operating margin | 3.4% | 2.2% | 4.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1.10% |
|---|---|
| Net profit, quarter on quarter | +69.00% |
| Revenue, year on year | +21.30% |
| Operating profit, year on year | -3.50% |
| Operating profit, quarter on quarter | +124.40% |
NSE results filing, NSE: MEDPLUS. Figures extracted from the filing.
Medplus Health Services Ltd: key numbers
- Share price
- ₹609.40
- Market cap
- ₹7,321 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 34.7×Sector 52.0×
- Promoter holding
- 40.19%+0.00% QoQ
- FII holding
- 12.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Earnings Call Transcript: Key Takeaways
Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.
- Call
- Guides 10% growth
Medplus Health Services Share Pledge
Catalyst Trusteeship pledged 34,00,000 Medplus Health Services shares (2.83%) as debenture collateral. Total encumbered shares rose to 2,41,50,400 (20.10% of capital).
Medplus Health Services Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,037cr (+21.3% YoY), operating EBITDA ₹98cr (4.8% margin), reported PAT ₹56cr (+1% YoY). Store expansion continues; no explicit guidance given.
Medplus Health Services Employee Stock Options
MedPlus allotted 19,095 equity shares to employees on exercise of ESOP 2021 options. Paid-up capital rises to Rs 24.03 Crore.
Medplus Health Services Adverse Business Impact
Optival Health, a MedPlus subsidiary, had drug licences suspended at five Karnataka stores for 1–7 days. Expected impact is about Rs 8.66 lakhs.
- Value
- ₹0.09 Cr
- Execution
- 1 to 7 days per store
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary Optival Health faced temporary drug license suspensions for two stores by Mysore regulators. The estimated operational impact is ₹0.02 Crore.
- Value
- ₹0.02 Cr